The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ellis, J. H.
Right arrow Articles by Crowe, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellis, J. H.
Right arrow Articles by Crowe, J. S.

The Journal of Immunology, Vol 155, Issue 2 925-937, Copyright © 1995 by American Association of Immunologists

ARTICLES

Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma

JH Ellis, KA Barber, A Tutt, C Hale, AP Lewis, MJ Glennie, GT Stevenson and JS Crowe
Molecular Immunology Group, Wellcome Foundation Ltd, Beckenham, Kent, United Kingdom.

Multiple myeloma is a malignancy of plasma cells for which there is no effective treatment. To develop an immunotherapeutic agent, we have raised a high affinity mAb (AT13/5) against CD38, one of the few well- characterized surface Ags present on myeloma cells. Since murine monoclonals have many disadvantages as human therapeutics, we prepared two engineered forms of the Ab: a CDR-grafted humanized IgG1 and a chimeric FabFc2 (mouse Fab cross-linked to two human gamma 1 Fc). To retain affinity in the humanized Ab, a number of changes were required to the human framework regions of the heavy chain. In particular, through systematic mutagenesis and computer modeling, we identified a critical interaction between the side chains of residues 29 and 78, which may be important for the humanization of other Abs. The properties of the humanized IgG1 and FabFc2 constructs were compared in a series of in vitro tests. Both constructs efficiently directed Ab- dependent cellular cytotoxicity against CD38-positive cell lines, but C was activated only poorly. Neither construct caused down-modulation of CD38, nor did they affect the NADase activity of CD38. Despite their differing structures, both Abs showed similar activity in most assays, although the humanized IgG1 was more potent at inducing monocyte cytotoxicity. These data represent the first direct comparison of CDR- grafted and chimeric FabFc2 forms of the same Ab, and offer no support for the perceived advantages of the FabFc2. These Abs show promise for therapy of multiple myeloma and other diseases involving CD38-positive cells.


This article has been cited by other articles:


Home page
 BloodHome page
D. C. Taussig, F. Miraki-Moud, F. Anjos-Afonso, D. J. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S. G. Agrawal, et al.
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
Blood, August 1, 2008; 112(3): 568 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
F. Malavasi, S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. Vaisitti, and S. Aydin
Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
Physiol Rev, July 1, 2008; 88(3): 841 - 886.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Frasca, G. Fedele, S. Deaglio, C. Capuano, R. Palazzo, T. Vaisitti, F. Malavasi, and C. M. Ausiello
CD38 orchestrates migration, survival, and Th1 immune response of human mature dendritic cells
Blood, March 15, 2006; 107(6): 2392 - 2399.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Ozaki, M. Kosaka, Y. Wakahara, Y. Ozaki, M. Tsuchiya, Y. Koishihara, T. Goto, and T. Matsumoto
Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells
Blood, June 1, 1999; 93(11): 3922 - 3930.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. H. T. Chan, J. Wang, R. R. French, and M. J. Glennie
Internalization of the Lymphocytic Surface Protein CD22 Is Controlled by a Novel Membrane Proximal Cytoplasmic Motif
J. Biol. Chem., October 23, 1998; 273(43): 27809 - 27815.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. L. Tutt, R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. E. Parkhouse, G. G. B. Klaus, and M. J. Glennie
Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors
J. Immunol., September 15, 1998; 161(6): 3176 - 3185.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Ozaki, M. Kosaka, S. Wakatsuki, M. Abe, Y. Koishihara, and T. Matsumoto
Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24
Blood, October 15, 1997; 90(8): 3179 - 3186.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. A. Kyle
Multiple Myeloma: An Overview in 1996
Oncologist, October 1, 1996; 1(5): 315 - 323.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.